Adrenergic Pharmacology Flashcards
(42 cards)
Synthesis of catecholamines
Tyrosine is taken up into the nerve terminal when it is hydroxylated to dihydrocyphenylalanine (DOPA) by tyrosine hydroxylase [note: this is the rate limiting step]. DOPA is decarboxylated to dopamine (DA) by aromatic L-amino acid decarboxylase.
Storage of catecholamines
DA actively transported into vesicle by vesicular monoamine transporter 2 (VMAT2) [promiscuous for all monoamines, susceptible to reserpine]. In the vesicle DA is hydroxylated to NE by dopamine beta-hydroxylase.
In the adrenal medulla NE is further N-methylated to epinephrine by phenylethanolamine-N-methyltransferase (PNMT)
Release of catecholamines
Influx of calcium causes vesicles to fuse with membranes. Guanethidine blocks
Presynaptic regulation of NE release
NE along with cotransmitters, neuropeptide Y and ATP, feedback on prejunctional receptors [alpha2, y2 and p1 respectively] to inhibit transmitter release. NE binding to beta2 results in enhanced neurotransmitter release
Termination of actions of catecholamines
Metabolism of catecholamines does not occur in synaptic cleft. Reuptake and dilution are responsible. [Note: reuptake via NET or DAT is blocked by cocaine, SSRIs, SNRIs and TCAs (imipramine)]
Catecholamine metabolism in nerve terminal
MAO is associated with the mitochondrial surface. Two subgroups: MOA-A preferentially metabolizes NE and 5-HT (serotonin). MAO-B like DA and phenylethylamine best. Both are found in the brain. A is also present in GI, liver, placenta and skin. B is in platelets and lymphocytes. Vanyllylmandelic acid is the major end product, renally excreted, ultra high levels present in pheochromocytoma.
alpha-methyltyrosine
blocks the synthesis of NE by inhibiting TH
methyldopa
inhibits AAADC and forms “false neurotransmitter,” alpha-methylnorepinephrine.
Bretylium and guanethidine
prevent release of NE
Tyramine, ephedrine and amphetamine
rapid, brief NE liberation both by displacing NE in extracellular fluid, and by facilitated exchange diffusion for the outward transport of NE. They also mobilize NE in vesicles by competing for vesicular uptake processes.
Alpha adrenergic receptors
epinephrine > norepinephrine»_space; isoproterenol.
alpha1 has a higher affinity for phenylephrine. Postsynaptic, constricts smooth muscle by Gq activation (PIP3 -> DAG and IP3 -> activation of protein kinase C and release of Ca++ resepectively.)
alpha2 selectively binds clonidine. Presynaptic, feedback inhibition, mediated by Gi and decreased cAMP levels. [Note: tamsulosin selectively treats BPH because it binds only alpha2A which is present in the urinary tract and not alpha2B in the blood vessels]
Beta adrenergic receptors
isoproterenol > epinephrine > norepinephrine.
Beta1 equal affinity for NE and E.
Beta2 higher affinity for E than NE (make it particularly responsive to circulating E)
Beta3 involved in lipolysis, detrussor muscle
All beta receptors are mediated by Gs to increase intracellular cAMP
Blood pressure control mechanisms
Cardiac output - dependent on venous return and heart rate (thus CO is under the control of RAAS and SANS)
Blood volume - dependent on renin-angiotensin-aldosterone system
Peripheral vascular resistance - dependent on RAAS and SANS
Baroreceptor reflex
A drop in blood pressure (as measured by the aortic arch and the carotid sinus) results in SANS firing which causes: increased heart rate, increase ventricular contractility, increase total peripheral resistance, and vascular tone.
An increase in blood pressure results in PANS firing causing a decrease in heart rate.
Reflex can be blocked by ganglion blocking drugs - hexamethonium. Reflex tachycardia can be blocked with beta1 antagonist. Reflex bradycardia can be blocked with muscarinic antagonist
Anti-hypertensive drugs
Can trigger ANS and endocrine feedback loops, resulting in tachycardia and salt and water retention. Beta blockers and diuretics are often part of anti-hypertensive regimens.
sympathomimetic drugs - direct acting agonist
Responses are not reduced by prior treatment with reserpine or guanethidine. Actions of direct-acting amines may actually increase after transmitter depletion because the loss of the endogenous neurotransmitter induces compensatory changes that up-regulate receptors
Sympathomimetic drugs - indirect-acting agonist
Act by releasing or displacing NE from vesicles, blocking reuptake of NE, blocking MAO or COMT. The response is abolished if there is prior treatment with reserpine or guanethidine
Sympathomimetic drugs - mixed-action agonist
Effects are blunted, but not abolished by prior treatment with reserpine or guanethidine
Epinephrine
Interacts with alpha and beta receptors (B>A). Effects are dose-dependent: low dose = beta effects (vasodilation). high dose = alpha effects (vasoconstriction).
Cardiovascular effects: Increase contractility and rate of contraction (positive ionotrope: beta1). Constricts arterioles in the skin, mucous membranes and viscera (alpha). Dilates liver and skeletal muscle vessels (beta2). Renal blood flow decreases. Increased systolic blood pressure with slightly decreased diastolic
Respiratory: powerful bronchodilator (beta2) and inhibits histamine release.
Hyperglycemia: glucose liberation (Beta2) and decreased insulin release (alpha2)
Lipolysis: beta2 on adipose tissue
Used to treat anaphylaxis, acute asthma, cardiac arrest, adjunct to local anesthetics.
Rapidly metabolized by MAO and COMT, metanephrine and vanillylmandelic acid excreted in urine.
Adverse effects include restlessness, tremor, tension, headache, and palpitation. Can induce cerebral hemorrhage and cardiac arrhythmia, diabetic patients may need to increase insulin doses
Norepinephrine
Direct acting catecholamine. Stimulates alpha1 > alpha2 > beta1
Cardiovascular effects include rise in peripheral resistance from vasoconstriction in most beds including kidney. Increase in systolic and diastolic BP. Does not induce compensatory vasodilation in skeletal muscle, weak B2 activity.
Baroreceptor reflex: NE increases BP, inducing rise in vagal activity causing reflex bradycardia. Preadministration of atropine blocks vagal transmission and NE stimulation of the heart can be seen as tachycardia.
Therapeutic use in treating shock.
Given IV, duration 1-2 minutes, MAO and COMT metabolism, excretion in urine.
Adverse Effects are similar to epinephrine with additional blanching, sloughing off of skin and necrosis associated with injection site due to extreme vasoconstriction. Impaired circulation can be treated with phentolamine
Isoproterenol
Direct-acting synthetic catecholamine, stimulates beta1 and 2, rarely used therapeutically,
Cardiovascular actions - intense stimulation of the heart, dilate skeletal muscle arterioles, greatly reduces mean arterial and diastolic blood pressure.
Potent bronchodilator, may still be useful intreating AV block.
Adverse effects similar to epinepthrine
Dopamine
direct-acting natural catecholamine, stimulates D1, beta1 and alpha1. Effects are dose dependent. low dose = just D1, high dose = D1, beta1, and alpha1.
Cardiavascular effects - positive inotropic and chronotropic effects, at very high dose stimulates alpha1 causing vasocontriction.
Renal and visceral effects - dilates renal and splanchnic arterioles
Therapeutic drug of choice for cardiogenic and septic shock, especially in the context of oliguria. Also used to treat hypotension and severe heart failure in patients with low or normal peripheral vascular resistance or oliguria.
Adverse effects - same as sympathetic stimulation, rapidly metabolized by MAO and COMT so effects are short lived.
Fenoldopam
Agonist of periperal dopamine D1 receptors. Used as a rapid active vasodilator to treat sever hypertension in hospitalized patients, acts of coronary arteries, kidney arterioles and mesenteric arteries
Adverse effects - headache, flushing, dizziness, nause, vomiting and tachycardia
Dobutamine
Synthetic direct-acting catecholamine, beta1 receptor agonist. Increases cardiac rate and output with few vascular effects. Used to increase CO in acute heart failure and MI, inotropic effect after cardiac surgery because it does not significantly increase O2 demands on myocardium.
Adverse effects - used with caution in atrial fibrillation, because it increases AV conductance, others similar to epinephrine. Tolerance may develop with prolonged use.